| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.07. | Sharp Therapeutics Corp (2): Sharp Therapeutics closes $1.36-million financing | 1 | Stockwatch | ||
| 29.07. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of Non-Brokered Private Placement | 454 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has... ► Artikel lesen | |
| SHARP THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.07. | Sharp Therapeutics Corp.: Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders | 514 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 21, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical biotechnology company developing... ► Artikel lesen | |
| 16.07. | Sharp Therapeutics Corp (2): Sharp Therapeutics arranges $1.36M private placement | 2 | Stockwatch | ||
| 15.07. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Non-Brokered Private Placement and Provides Operational Update | 348 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it is... ► Artikel lesen | |
| 30.06. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Filing of Amended and Restated Management Information Circular and New Annual Meeting Date | 579 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces that its annual meeting... ► Artikel lesen | |
| 09.06. | Sharp Therapeutics Corp (2): Sharp Therapeutics debenture private placement | 1 | Stockwatch | ||
| 28.05. | Sharp Therapeutics Presents New Preclinical Data Supporting Novel Small-Molecule Therapeutic Approach for Niemann-Pick Disease Type C | 3 | GlobeNewswire (USA) | ||
| 18.04. | Sharp Therapeutics Corp.: Sharp Therapeutics Corp. Announces Fourth Quarter 2025 Results, Closing of Convertible Note Offering and Adoption of Semi-Annual Reporting | 966 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 17, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its annual... ► Artikel lesen | |
| 10.04. | Sharp Therapeutics Corp.: Sharp Therapeutics Updates on '901 for Gaucher and GBA1 Parkinson's and Platform Programs | 1.076 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces that following longer-term... ► Artikel lesen | |
| 10.04. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of Fourth Tranche of Unsecured Convertible Note Offering | 1.147 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it... ► Artikel lesen | |
| 02.04. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of Third Tranche of Unsecured Convertible Note Offering | 1.071 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has... ► Artikel lesen | |
| 13.03. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of Second Tranche of Unsecured Convertible Note Offering | 947 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - March 13, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it... ► Artikel lesen | |
| 27.02. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of First Tranche of Unsecured Convertible Note Offering | 723 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that... ► Artikel lesen | |
| 02.02. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes | 410 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce the terms... ► Artikel lesen | |
| 19.12.25 | Sharp Therapeutics Corp.: Sharp Therapeutics Provides Update on Non-Brokered Private Placement and Grant of Options | 687 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - December 19, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), is pleased to announce that... ► Artikel lesen | |
| 26.11.25 | Sharp Therapeutics Corp. Reports Third Quarter 2025 Results and Development Update | 465 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - November 26, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), announces the release of its condensed... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,200 | -0,24 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| COGENT BIOSCIENCES | 27,850 | +1,49 % | Cogent Biosciences auf Jefferies-Konferenz: Markteinführungspläne hängen an Bezuclastinib | ||
| CG ONCOLOGY | 78,93 | -6,90 % | Truist hebt Kursziel für CG Oncology nach Studiendaten an | ||
| SUMMIT THERAPEUTICS | 10,660 | -9,81 % | Summit Therapeutics (SMMT) Hits 52-Week Low After FDA Setback | ||
| PRAXIS PRECISION MEDICINES | 305,32 | -1,60 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| ERASCA | 13,900 | -7,95 % | Warum die Erasca-Aktie heute nachgibt: Düstere Verlustprognosen belasten den Kurs | ||
| TREVI THERAPEUTICS | 13,510 | +1,66 % | Trevi Therapeutics: Wie ein Nischenmedikament zum strategischen Hebel für den Milliardenmarkt Reizhusten werden könnte | Trevi Therapeutics steht kurz davor, mit Haduvio ein erstes Nischenprodukt in den US-Markt zu bringen und damit einen "specialty beachhead" zu etablieren, der als Plattform für eine mögliche Expansion... ► Artikel lesen | |
| BEAM THERAPEUTICS | 20,640 | -1,43 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| EDGEWISE THERAPEUTICS | 42,020 | -3,80 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 2,720 | -6,37 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| JADE BIOSCIENCES | 15,400 | +0,42 % | Jade Biosciences forciert Autoimmun-Pipeline: Ambitionierte Pläne im 20-Milliarden-Dollar-Markt | ||
| KYMERA THERAPEUTICS | 121,49 | -3,43 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 51,11 | +2,80 % | Travere Therapeutics auf der Jefferies Global Healthcare Conference: Starkes FILSPARI-Wachstum, Pipeline-Fortschritte und verlängerter Patentschutz bis 2037 | ||
| TANGO THERAPEUTICS | 22,120 | -8,48 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| RAPPORT THERAPEUTICS | 23,760 | -4,27 % | Rapport Therapeutics präsentiert Pipeline-Fortschritte und Phase-III-Fahrplan auf der Jefferies Global Healthcare Conference |